Trial register facet
Trial records in type 2 diabetes mellitus — page 2
247 records bearing on type 2 diabetes mellitus.
Showing 0 records on this page
Records
247 documents · page 2 of 11
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| ACHIEVE-1-QOLprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2-ADHERENCEprogramme record | Orforglipron | Phase 3 | Reported | Observational | — | 2025 | Very low |
| REDEFINE-2-BIOMARKERprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SOUL-DDIprogramme record | Semaglutide, oral | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| STRIDE-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURPASS-CVOT-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| ACHIEVE-2-BIOMARKERprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-ADHERENCEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Observational | — | 2025 | Very low |
| SOUL-HEPATIC-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| ECNO-PH3-CN-T2D-REGIONAL-CNprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| STEP-HFpEF-DM | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 616 | 2024 | Moderate |
| FLOW | Semaglutide | Phase 3 | Reported | Event-driven kidney outcome trial | 3,533 | 2024 | High |
| DREAMS-1 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 319 | 2024 | Moderate |
| DREAMS-2 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 731 | 2024 | Moderate |
| MARITIDE-PH2-T2D | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Low |
| STEP-HFpEF-DM-BODY-COMPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| FLOW-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| MARITIDE-PH2-T2D-REGIONAL-JPprogramme record | Maridebart cafraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| DREAMS-2-RENAL-IMPprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| MARITIDE-PH2-T2D-BODY-COMPprogramme record | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| DREAMS-2-PKprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| MARITIDE-PH2-T2D-REGIONAL-CNprogramme record | Maridebart cafraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
page 2 of 11